导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.82% | 3512/4764 |
| 近一周 | -2.78% | 4647/5455 |
| 近一月 | 2.02% | 177/5409 |
| 近一季 | 3.41% | 489/5227 |
| 近半年 | -1.66% | 2036/4921 |
| 近一年 | -3.97% | 3090/4391 |
| 近两年 | 33.51% | 2135/2946 |
| 近三年 | 27.71% | 1158/2246 |
| 成立以来 | 190.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.30% 4361/4961 |
-4.65% 3522/5312 |
- - |
- - |
| 2025 | 11.10% 2764/4813 |
-1.35% 2643/3635 |
9.08% 299/4076 |
-1.84% 3968/4524 |
5.18% 462/4813 |
| 2024 | 35.66% 52/3463 |
3.71% 520/2808 |
1.92% 428/3014 |
25.15% 313/3129 |
2.55% 935/3463 |
| 2023 | -5.31% 727/2656 |
-1.56% 1876/2280 |
0.65% 290/2385 |
4.61% 145/2515 |
-8.65% 2302/2655 |
| 2022 | -11.07% 228/2207 |
-5.77% 206/1919 |
-0.09% 1592/2016 |
-10.50% 416/2113 |
5.55% 458/2208 |
| 2021 | -4.50% 952/1822 |
-0.33% 353/1255 |
-1.50% 1169/1330 |
-3.67% 651/1466 |
0.97% 1031/1822 |
| 2020 | 14.57% 792/1250 |
-13.47% 929/1028 |
7.61% 837/1067 |
14.24% 289/1164 |
7.70% 699/1184 |
| 2019 | 37.84% 328/1092 |
27.21% 354/754 |
2.14% 97/804 |
-1.56% 666/850 |
7.77% 398/918 |
| 2018 | -16.43% 108/834 |
- - |
- - |
- - |
-9.18% 134/691 |
| 2017 | 22.90% 143/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.51% 175/605 |
- - |
- - |
- - |
- - |
| 2015 | -5.88% 277/575 |
- - |
- - |
- - |
- - |
| 2014 | 89.11% 2/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国投瑞银金融地产ETF VS. 长安沪深300非周期A(740101) |